MannKind Corporation Reports Third Quarter Financial Results
VALENCIA, Calif., Nov. 7 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the third quarter ended September 30, 2007.
For the third quarter of 2007, total operating expenses were $75.6 million, compared to $61.1 million for the third quarter of 2006. A substantial portion of this increase was attributed to increased research and development (R&D) expenses which totaled $64.8 million for this quarter compared to $50.8 million for the same quarter in 2006. These increased R&D costs were associated with the Company's expanded clinical development program and the associated manufacturing costs (including clinical supplies) for Technosphere Insulin. General and administrative (G&A) expenses increased by $0.4 million to $10.7 million for the third quarter of 2007 compared to the third quarter of 2006. This increase was due primarily to the increased number of employees.
For the first nine months of 2007, operating expenses totaled $228.3 million, compared to $162.0 million in the first nine months of 2006. R&D expenses were $190 million, up $58.0 million as compared to the first nine months of 2006, again primarily related to the Company's expanded clinical development program and the associated manufacturing costs (including clinical supplies) for Technosphere Insulin. G&A expenses increased by $8.3 million to $38.2 million for the first nine months of 2007 compared to the first nine months of 2006 primarily related to the increased number of employees and increased professional fees.
The net loss for the third quarter of 2007 was $73.0 million, or $0.99 per share, based on 73.5 million weighted average shares outstanding. This compares to a net loss of $61.0 million, or $1.23 per share, based on 49.7 million weighted average shares outstanding for the third quarter of 2006.
The net loss for the first nine months of 2007 was $218.2 million, or $2.97 per share based on 73.4 million weighted average shares outstanding, compared with a net loss of $159.3 million, or $3.20 per share based on 49.7 million weighted average shares outstanding, for the first nine months of 2006.
Cash, cash equivalents and marketable securities were $204.2 million at September 30, 2007, $284.0 million at June 30, 2007, and $436.5 million at December 31, 2006. On October 5, 2007 the company received $250 million in gross proceeds from its self managed registered direct offering of approximately 27 million shares of common stock.
"While Exubera stumbled in the marketplace and then was ultimately withdrawn, our Technosphere Insulin is very different and continues to be well received by patients and physicians in our clinical trials," stated Alfred Mann, Chairman and Chief Executive Officer. "Our Phase 3 program is on track and our readiness for commercial operations is proceeding according to schedule. As data becomes available in 2008, we will be able to share more of this progress with our investors. In the meantime, the recently announced positive Phase 1 data for our Technosphere/GLP-1 product were encouraging. More than ever, there is a need for improved and innovative diabetes therapies. We at MannKind remain committed to bringing such therapies to the enormous number of diabetes patients who suffer from this disease."
MannKind management will host a conference call to discuss these results today at 8:00 a.m. Eastern Time. To participate in the call please dial (888) 566-5775 or (210) 234-0001. To listen to the call via the Internet please visit http://www.mannkindcorp.com. The web site replay will be available for fourteen days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (800) 262-4859 or (203) 369-3220.
Presenting from the Company will be:
- Chairman and Chief Executive Officer Alfred Mann
- President and Chief Operating Officer Hakan Edstrom
- Corporate Vice President and Chief Financial Officer Dick Anderson
- Corporate Vice President and Chief Scientific Officer Peter Richardson
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product, the Technosphere Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.
This press release contains forward-looking statements, including statements related to the anticipated availability of clinical trial data in 2008, MannKind's commitment to develop diabetes therapies, the status of MannKind's Phase 3 program, and MannKind's readiness for commercial operations. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations and involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of clinical trials, difficulties or delays in seeking or obtaining regulatory approval, MannKind's ability to enter into any collaborations or strategic partnerships, MannKind's ability to raise additional financing and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2006 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this news release.
(Tables to follow) MannKind Corporation Consolidated Statements of Operations (Unaudited) (in thousands, except per share amounts) Three Months Ended Nine Months Ended Sept. 30, Sept. 30, Sept. 30, Sept. 30, 2007 2006 2007 2006 Revenue $- $- $10 $100 Operating expenses: Research and development 64,825 50,785 190,093 132,056 General and administrative 10,744 10,349 38,207 29,943 Total operating expenses 75,569 61,134 228,300 161,999 Loss from operations (75,569) (61,134) (228,290) (161,899) Other income 62 51 158 160 Interest expense on senior convertible notes (778) - (2,824) - Interest expense on note payable to principal stockholder - (689) - (689) Interest income 3,238 802 12,779 3,153 Loss before provision for income taxes (73,047) (60,970) (218,177) (159,275) Income taxes - - - (5) Net loss $(73,047) $(60,970) $(218,177) $(159,280) Net loss - basic and diluted $(0.99) $(1.23) $(2.97) $(3.20) Shares used to compute basic and diluted net loss per share 73,520 49,731 73,444 49,718 MannKind Corporation Condensed Balance Sheet (Unaudited) (in thousands) September 30, December 31, Assets 2007 2006 Current assets: Cash and cash equivalents $152,298 $319,555 Marketable securities 51,875 116,924 State research and development tax credit exchange receivable - current 3,171 2,418 Prepaid expenses and other current assets 11,876 10,650 Total current assets 219,220 449,547 Property and equipment - net 143,244 88,328 State research and development tax credit exchange receivable - net of current portion 1,125 1,500 Other assets 547 362 Total $364,136 $539,737 Liabilities and Stockholders' Equity Current liabilities $72,847 $44,959 Other liabilities 24 24 Senior convertible notes 111,641 111,267 Stockholders' equity 179,624 383,487 Total $364,136 $539,737
SOURCE MannKind Corporation
Chief Financial Officer,
of MannKind Corporation;
investors, Robert Stanislaro,
for MannKind Corporation
Web site: http://www.mannkindcorp.com